Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 15/20 | 0.76 |
| ▸ | JAK2 | O60674 | 2/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.59 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9917860 | 0.94 | PRKCQ (0.73) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL9917841 | 0.90 | PRKCQ (0.79) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL9917742 | 0.89 | PRKCQ (0.84) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL9917842 | 0.86 | PRKCQ (1.00) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL9917843 | 0.86 | PRKCQ (1.00) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL9917732 | 0.86 | PRKCQ (1.00) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL9917838 | 0.85 | PRKCQ (0.77) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL9917825 | 0.84 | PRKCQ (1.00) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL9917736 | 0.84 | PRKCQ (0.79) | PRKCQJAK2ROCK2PRKCDROCK1 | |
| SCHEMBL9917795 | 0.83 | PRKCQ (0.76) | PRKCQJAK2ROCK2PRKCDROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367697-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367697-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120149680-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149680-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-14 | — | — | US | disclosed |
| US-8173635-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173635-B2 | Kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-08 | — | — | US | disclosed |
| US-20090291937-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
| US-20090291937-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291937-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCQ 38/4885JAK2 133/4885ROCK2 287/4885 |
| US-20120149680-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | PRKCQ 38/4885JAK2 133/4885ROCK2 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.